Author

Montserrat Rivero

THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU
THE INFLUENCE OF PREOPERATIVE MEDICATIONS IN SURGICAL COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE IN SPAIN: A MULTICENTER STUDY OF GETECCU

Montserrat Rivero  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

Montserrat Rivero  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

Montserrat Rivero  et al.

EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY
EFFECTIVENESS AND SAFETY OF SWITCHING FROM ADALIMUMAB REFERENCE TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: THE ADA-SWITCH STUDY

Montserrat Rivero  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

Montserrat Rivero  et al.

CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MALIGNANT SMALL BOWEL NEOPLASIAS: PROGNOSIS OF A SILENT ENTITY
CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF MALIGNANT SMALL BOWEL NEOPLASIAS: PROGNOSIS OF A SILENT ENTITY

Montserrat Rivero  et al.

MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY
MANAGEMENT AND OUTCOME OF POSTOPERATIVE CROHN’S DISEASE IN THE ELDERLY AS COMPARED TO YOUNG ADULTS: DATA FROM ENEIDA REGISTRY

Montserrat Rivero  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Montserrat Rivero  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Montserrat Rivero  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Montserrat Rivero  et al.

INCREASED RISK OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN INFLAMMATORY BOWEL DISEASE INDEPENDENT OF CLASSIC METABOLIC RISK FACTORS
INCREASED RISK OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE AND ADVANCED FIBROSIS IN INFLAMMATORY BOWEL DISEASE INDEPENDENT OF CLASSIC METABOLIC RISK FACTORS

Montserrat Rivero  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Montserrat Rivero  et al.

MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU
MANAGEMENT OF PATIENTS NEWLY DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE BASED ON HOSPITAL CHARACTERISTICS: RESULTS FROM THE NATIONWIDE EPIDEMIBD STUDY OF GETECCU

Montserrat Rivero  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Montserrat Rivero  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Montserrat Rivero  et al.

INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)
INFLAMMATORY BOWEL DISEASE IN IMMIGRANTS TO SPAIN: RESULTS OF THE EIIMIGRA STUDY FROM GETECCU (ENEIDA REGISTRY)

Montserrat Rivero  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

Montserrat Rivero  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Montserrat Rivero  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Montserrat Rivero  et al.

RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY
RISK AND PREDICTORS OF SURGERY IN A NEWLY DIAGNOSED COHORT OF IBD PATIENTS IN THE BIOLOGIC ERA: RESULTS FROM THE EPIDEMIBD STUDY

Montserrat Rivero  et al.

Item 1 - 20 / 22
1
2